Cullinan Oncology, Inc. (NASDAQ:CGEM - Get Free Report)'s share price was up 7.8% during trading on Wednesday . The stock traded as high as $18.24 and last traded at $17.97. Approximately 153,899 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 477,343 shares. The stock had previously closed at $16.67.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on CGEM. BTIG Research lifted their target price on Cullinan Oncology from $20.00 to $30.00 and gave the company a "buy" rating in a research report on Wednesday, April 17th. Jonestrading lifted their price objective on shares of Cullinan Oncology from $22.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, April 17th. HC Wainwright lowered their target price on shares of Cullinan Oncology from $34.00 to $29.00 and set a "buy" rating for the company in a report on Tuesday, April 16th. William Blair assumed coverage on shares of Cullinan Oncology in a report on Monday, April 15th. They set an "outperform" rating on the stock. Finally, Wedbush began coverage on shares of Cullinan Oncology in a research report on Thursday, February 15th. They issued an "outperform" rating and a $30.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $28.75.
Read Our Latest Analysis on Cullinan Oncology
Cullinan Oncology Price Performance
The business's fifty day moving average is $17.14 and its 200-day moving average is $12.82. The firm has a market cap of $813.59 million, a PE ratio of -4.82 and a beta of 0.33.
Cullinan Oncology (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.42. Analysts forecast that Cullinan Oncology, Inc. will post -3.21 EPS for the current year.
Insider Transactions at Cullinan Oncology
In other Cullinan Oncology news, insider Corrine Savill sold 40,000 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $16.18, for a total transaction of $647,200.00. Following the sale, the insider now owns 165,990 shares of the company's stock, valued at approximately $2,685,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.82% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in CGEM. SG Americas Securities LLC bought a new position in shares of Cullinan Oncology in the third quarter valued at approximately $116,000. Bank of New York Mellon Corp grew its position in shares of Cullinan Oncology by 11.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 97,159 shares of the company's stock valued at $879,000 after purchasing an additional 9,989 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Cullinan Oncology by 1,331.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,542 shares of the company's stock worth $59,000 after buying an additional 6,085 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Cullinan Oncology by 380.1% during the third quarter. Assenagon Asset Management S.A. now owns 609,106 shares of the company's stock valued at $5,512,000 after buying an additional 482,234 shares during the period. Finally, Barclays PLC grew its position in Cullinan Oncology by 145.6% during the third quarter. Barclays PLC now owns 53,393 shares of the company's stock worth $483,000 after buying an additional 31,650 shares in the last quarter. Hedge funds and other institutional investors own 86.31% of the company's stock.
About Cullinan Oncology
(
Get Free Report)
Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cullinan Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Oncology wasn't on the list.
While Cullinan Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
